Clinical trials: Vaccination
Influenza
Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
We hypothesize that when offered influenza vaccine at little or no cost, in a setting where the value of the vaccine is connected to one's high risk child, vaccination rates for parents will approach 90-95%, similar to rates…
- Trial name
- NCT00812110
- Testing
- Influenzae vaccine
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Akron Children's Hospital
Colorectal Cancer
Pilot Study of GVAX in Colorectal Cancer Cells
This study is a Pilot clinical trial. Pilot clinical trials test the safety of an investigational combination of drugs. Pilot studies provide information on what effects, both good and bad, the Investigational agent might have on…
- Trial name
- NCT01952730
- Testing
- GVAX
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Triple Negative Breast Cancer, Breast Neoplasms
Vaccination of Triple Negative Breast Cancer Patients
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast…
- Trial name
- NCT02938442
- Testing
- P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Arkansas
Asthma
Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma is a major health problem in preschool children. Infections by pneumococci a the most frequent cause of airway infections, which tend to cause worsening of asthma.
- Trial name
- PAPSI (NCT00836641)
- Testing
- prevenar, pneumovax
- Volunteers
- 70 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Myelodysplastic Syndromes
Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Vaccines made from cancer cells may help the body build an effective immune response to kill abnormal cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with…
- Trial name
- NCT00361296
- Testing
- K562/GM-CSF cell vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV Exposure, HIV Infection
Early Versus Delayed BCG Vaccination of HIV-exposed Infants
In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected children develop AIDS and die faster in SSA than those in developed countries.
- Trial name
- NCT02062580
- Testing
- BCG
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Influenza Immunity in Children
This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to…
- Trial name
- NCT02559505
- Testing
- Seasonal IIV 0.25 mL dose, Natural influenza infection, Seasonal IIV 0.5 mL dose
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccinations…
- Trial name
- NCT00368966
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7-valent Pneumococcal Conjugate Vaccine
- Where
- 41 sites in Spain
- Volunteers
- 619 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Meningococcal
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' MenACWY-TT vaccine administered at 6 years post-primary vaccination with either GSK Biologicals'…
- Trial name
- NCT01777308
- Testing
- Meningococcal conjugate vaccine GSK134612
- Where
- 8 sites in Australia
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Immunisation, Diphtheria Immunisation
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation
- Trial name
- NCT04398706
- Testing
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3
- Where
- 57 sites in United States, Canada and 2 more
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Simplifying the Rabies Pre-exposure Vaccination
Rabies is a viral zoonosis that causes an encephalitis, almost invariably fatal. It is widely distributed across the globe: the World Health Organization (WHO) estimates that about 2,4 billion people live in endemic areas for…
- Trial name
- NCT01388985
- Testing
- Human Diploid Cell Vaccine (HDCV) rabies vaccine
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children
Influenza remains a potentially significant and largely preventable source of morbidity and mortality, yet vaccine coverage is low.
- Trial name
- NCT01662583
- Testing
- Text Message, Written reminder
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- Columbia University
Malignant Glioma
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
This is a single-institution Phase I/II study designed to evaluate the safety and induction of an immune response, and preliminary clinical response of vaccinations with Type-1 alpha-DCs (alpha-DC1) loaded with glioma-associated…
- Trial name
- NCT00766753
- Testing
- Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Frank Lieberman
Prostate Cancer
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
This was a Phase 1, open-label, fixed-dose study of immunization with the NY-ESO-1 protein combined with CpG 7909 as an adjuvant in patients with histopathologically confirmed, high-risk Stage D1 or advanced prostate cancer.
- Trial name
- NCT00292045
- Testing
- NY-ESO-1 protein/CpG 7909
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children
This study will aim to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' 10-valent pneumococcal conjugate vaccine GSK1024850A when co-administered with Japanese DTPa vaccine as a 3-dose…
- Trial name
- NCT01027845
- Testing
- Pneumococcal vaccine GSK1024850A, DTPa
- Where
- 16 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HPV Vaccine Acceptability
A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men
The purposes of this study are to (1) identify predictors of Human papillomavirus (HPV) vaccine acceptability among college men based on the Health Belief Model through focus groups, (2) triangulate focus group results with a…
- Trial name
- NCT01431079
- Testing
- HPV vaccine acceptability
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Prospective, Single-blind
Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.
In high-income societies the use of health care and medication is steadily increasing. Children have high morbidity, many visits at the general practitioner, an increasing number of hospitalisations, and an increasing use of…
- Conditions
- Prospective, Single-blind, Clinical, Trial
- Trial name
- NCT01694108
- Testing
- BCG-vaccine (SSI)
- Where
- 3 sites in Denmark
- Volunteers
- 4,262 people
- Sponsor
- Lone Graff Stensballe
Smallpox
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
The primary objective of this study is to evaluate the immune response after a single vaccination of pre-immune subjects compared to two vaccinations in naive subjects.
- Trial name
- NCT00316524
- Testing
- MVA-BN® (IMVAMUNE)
- Where
- Germany
- Volunteers
- 745 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic